Identification of factors limiting patient recruitment into phase I trials: A study from the Royal Marsden Hospital

被引:29
作者
Karavasilis, Vasilios [1 ]
Digue, Laurence [1 ]
Arkenau, Tobias [1 ]
Eaton, David [1 ]
Stapleton, Sarah [1 ]
de Bono, Johann [1 ]
Judson, Ian [1 ]
Kaye, Stan [1 ]
机构
[1] Royal Marsden Hosp, Drug Dev Unit, Sutton SM2 5PT, Surrey, England
关键词
phase I trials; recruitment; limiting factors;
D O I
10.1016/j.ejca.2008.02.040
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim: To identify factors that may prevent or delay patients referred for consideration of phase I studies from commencing such a study. Methods: A retrospective audit of phase I study referrals for the period 1st March to 31st August 2005 to the Drug Development Unit was performed. All reasons that led to either delay or recruitment failure were documented and analysed. Results: Data from 176 patients (105M/71F) were analysed. Median age at referral was 59 years and median performance status (PS) was 1. Of these, 56 (32%) were successfully recruited in a phase I trial. The median time from trial allocation to commencement of treatment was 4.8 weeks. Poor or deteriorating PS was the reason for delay or recruitment failure in 43 (35%) of non-recruited patients. Conclusions: Poor or deteriorating PS was the most common factor limiting accrual to phase I trials. Better patients' selection on this basis might improve recruitment rates. (c) 2008 Elsevier Ltd. All rights reserved.
引用
收藏
页码:978 / 982
页数:5
相关论文
共 10 条
[1]   Dynamic and modern: Bringing the ethics of phase I trials up to date [J].
Camidge, D. Ross ;
Eckhardt, S. Gail ;
Gore, Lia .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (32) :5178-5179
[2]   Rate limiting factors in recruitment of patients to clinical trials in cancer research: descriptive study [J].
Corrie, P ;
Shaw, J ;
Harris, R .
BMJ-BRITISH MEDICAL JOURNAL, 2003, 327 (7410) :320-321
[3]  
Daugherty Christopher K, 2004, Clin Adv Hematol Oncol, V2, P358
[4]   Ethical issues in the development of new agents [J].
Daugherty, CK .
INVESTIGATIONAL NEW DRUGS, 1999, 17 (02) :145-153
[5]   Cancer biology - Signatures guide drug choice [J].
Downward, J .
NATURE, 2006, 439 (7074) :274-275
[6]   Barriers in phase I cancer clinical trials referrals and enrollment: five-year experience at the Princess Margaret Hospital [J].
Ho, Jeremy ;
Pond, Gregory R. ;
Newman, Colin ;
Maclean, Martha ;
Chen, Eric X. ;
Oza, Amit M. ;
Siu, Lillian L. .
BMC CANCER, 2006, 6 (1)
[7]   Risks and benefits of phase 1 oncology trials, 1991 through 2002 [J].
Horstmann, E ;
McCabe, MS ;
Grochow, L ;
Yamamoto, S ;
Rubinstein, L ;
Budd, T ;
Shoemaker, D ;
Emanuel, EJ ;
Grady, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2005, 352 (09) :895-904
[8]  
KAITIN K, 2008, MOL THER, V83, P210
[9]   Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment [J].
Lara, PN ;
Higdon, R ;
Lim, N ;
Kwan, K ;
Tanaka, M ;
Lau, DHM ;
Wun, T ;
Welborn, J ;
Meyers, FJ ;
Christensen, S ;
O'Donnell, R ;
Richman, C ;
Scudder, SA ;
Tuscano, J ;
Gandara, DR ;
Lam, KS .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1728-1733
[10]   Cancer biology - Emissaries set up new sites [J].
Steeg, PS .
NATURE, 2005, 438 (7069) :750-751